2023
A Simple Prediction Model of Outcomes after Allogeneic Hematopoietic Stem Cell Transplant (HCT) in Myelodysplastic Syndromes Using HCT-Comorbidity Index, Cytogenetic Risk, and Platelet Count
Frumm S, Kim H, Kelkar A, Ho V, Gooptu M, Gibson C, Koreth J, Shapiro R, Romee R, Nikiforow S, Antin J, Soiffer R, Rolles B, Shimony S, Bewersdorf J, Kewan T, Alhajahjeh A, Luskin M, Garcia J, Chen E, Lane A, Wadleigh M, Winer E, Stone R, DeAngelo D, Zeidan A, Lindsley C, Cutler C, Stahl M. A Simple Prediction Model of Outcomes after Allogeneic Hematopoietic Stem Cell Transplant (HCT) in Myelodysplastic Syndromes Using HCT-Comorbidity Index, Cytogenetic Risk, and Platelet Count. Blood 2023, 142: 2246. DOI: 10.1182/blood-2023-185315.Peer-Reviewed Original ResearchHematopoietic stem cell transplantHCT comorbidity indexNon-relapse mortalityPost-HCT outcomesAllogeneic hematopoietic stem cell transplantStem cell transplantMyelodysplastic syndromePlatelet countPre-HCTMultivariable analysisUnivariable analysisRisk scoreHMA cyclesCytogenetic riskCell transplantHigh riskFour-year overall survivalDana-Farber Cancer InstituteSimplified prognostic modelHost disease (GVHD) prophylaxisReduced intensity conditioningNext-generation sequencingHigh-risk scoreRespective risk groupsResource limited settingsSurvival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
Badar T, Atallah E, Shallis R, Saliba A, Patel A, Bewersdorf J, Grenet J, Stahl M, Duvall A, Burkart M, Palmisiano N, Bradshaw D, Kubiak M, Dinner S, Goldberg A, Abaza Y, Murthy G, Kota V, Litzow M. Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Leukemia 2023, 37: 799-806. PMID: 36807649, DOI: 10.1038/s41375-023-01847-7.Peer-Reviewed Original ResearchConceptsEvent-free survivalAllo-HSCTOverall survivalChronic GVHDAllogeneic hematopoietic stem cell transplantAllogeneic stem cell transplantationMedian event-free survivalHematopoietic stem cell transplantAcute myeloid leukemia patientsMedian overall survivalPost allo-HSCTReduced intensity conditioningStem cell transplantStem cell transplantationLong-term outcomesMyeloid leukemia patientsMulti-center studyAcute graftComplete remissionHost diseaseSalvage therapyComplex cytogeneticsMyeloablative conditioningMedian ageCell transplant
2020
Blast MRD CML 1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- a Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: A Trial of the ECOG-ACRIN Cancer Research Group (EA9171)
Zeidan A, Wang V, Radich J, Bewersdorf J, Bhatt V, Sharon E, Gore S, Luger S, Litzow M. Blast MRD CML 1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- a Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: A Trial of the ECOG-ACRIN Cancer Research Group (EA9171). Blood 2020, 136: 1. DOI: 10.1182/blood-2020-137734.Peer-Reviewed Original ResearchUndetectable minimal residual diseaseChronic myeloid leukemiaMeasurable residual diseaseTyrosine kinase inhibitorsTKI discontinuationTKI therapyMinimal residual diseaseCML patientsResidual diseaseMyeloid leukemiaBristol-Myers SquibbPembrolizumab therapyAdverse eventsPD-1T cellsCML cellsAnti-PD-1/PD-L1 therapyBlast phase chronic myeloid leukemiaPilot phase II clinical trialThird-line tyrosine kinase inhibitorsAllogeneic hematopoietic stem cell transplantAnti-PD-1 monoclonal antibodyPD-1/PD-L1Anti-PD-1 pembrolizumabDetectable minimal residual diseaseClinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience*
Bewersdorf JP, Shallis RM, Gowda L, Wei W, Hager K, Isufi I, Kim TK, Pillai MM, Seropian S, Podoltsev NA, Gore SD, Siddon AJ, Zeidan AM. Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience*. Leukemia & Lymphoma 2020, 61: 2180-2190. PMID: 32362171, PMCID: PMC7603787, DOI: 10.1080/10428194.2020.1759051.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMedian overall survivalTherapy-related malignanciesOverall survivalMyelodysplastic syndromeMyeloid leukemiaAllogeneic hematopoietic stem cell transplantLonger median overall survivalSingle-center retrospective studyComplex karyotypeHematopoietic stem cell transplantIntensive chemotherapy approachesYale Cancer CenterCharacteristics of patientsSingle-center experienceMinority of patientsStem cell transplantLong-term survivalLow response rateIntensive chemotherapyCenter experienceClinicopathologic characteristicsAdverse prognosisAML patientsCell transplant
2019
One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic stem cell transplant
Bewersdorf JP, Stahl M, Zeidan AM. One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic stem cell transplant. Expert Review Of Hematology 2019, 12: 575-578. PMID: 31225770, DOI: 10.1080/17474086.2019.1635005.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAntigens, CDAzacitidineCD8-Positive T-LymphocytesClinical Trials as TopicDrug Therapy, CombinationFemaleHematopoietic Stem Cell TransplantationHumansLenalidomideLeukemia, Myeloid, AcuteLymphocyte Activation Gene 3 ProteinMaleMiddle AgedMyelodysplastic SyndromesProgrammed Cell Death 1 ReceptorRecurrenceTransplantation, HomologousConceptsAcute myeloid leukemiaHematopoietic stem cell transplantStem cell transplantMyelodysplastic syndromeMyeloid leukemiaAllo-HSCTCell transplantAllogeneic hematopoietic stem cell transplantResponse rateAllogeneic stem cell transplantationNovel salvage therapiesPhase Ib studyStem cell transplantationOverall response rateCycles of treatmentCases of graftHigh response rateMechanism of actionCombination lenalidomideSalvage therapyHost diseaseMost patientsCurative treatmentCombination therapyDisease stageHealthcare expenses for treatment of acute myeloid leukemia
Bewersdorf JP, Shallis R, Wang R, Huntington S, Perreault S, Ma X, Zeidan AM. Healthcare expenses for treatment of acute myeloid leukemia. Expert Review Of Hematology 2019, 12: 641-650. PMID: 31159602, DOI: 10.1080/17474086.2019.1627869.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHematopoietic stem cell transplantInsurance statusHealthcare costsTreatment approachesAllogeneic hematopoietic stem cell transplantAcute myeloid leukemia (AML) treatmentStem cell transplantTreatment costsDirect healthcare costsInpatient treatment costsPatient insurance statusPersonalized treatment approachesAcute myeloid leukemiaMyeloid leukemia treatmentInfluence health policyIntensive chemotherapyOral therapyCell transplantMain cost driversMyeloid leukemiaNovel agentsMedical outcomesLeukemia treatmentHealthcare resourcesAML
2018
Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
Liu Y, Bewersdorf JP, Stahl M, Zeidan AM. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era? Blood Reviews 2018, 34: 67-83. PMID: 30553527, DOI: 10.1016/j.blre.2018.12.001.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHematopoietic stem cell transplantAcute myeloid leukemiaImmune checkpoint inhibitorsMyelodysplastic syndromeCheckpoint inhibitorsCell-based therapiesMyeloid leukemiaAllogeneic hematopoietic stem cell transplantCytotoxic T-lymphocyte-associated protein 4T-lymphocyte-associated protein 4Cell death protein 1Cell-based vaccinesNK cell therapyApplication of immunotherapyDeath protein 1Stem cell transplantAntibody-targeted therapyChimeric antigen receptorAntibody-based therapiesGemtuzumab ozogamicinDendritic cellsCell transplantImmunotherapeutic drugsT cellsClinical development